Multiple Myeloma, Version 3.2017, NCCN Clinical Practice Guidelines in Oncology
Open accessAbstract
Multiple myeloma (MM) is caused by the neoplastic proliferation of plasma cells. These neoplastic plasma cells proliferate and produce monoclonal immunoglobulin in the bone marrow causing skeletal damage, a hallmark of multiple myeloma. Other MM-related complications include hypercalcemia, renal insufficiency, anemia, and infections. The NCCN Multiple Myeloma Panel members have developed guidelines for the management of patients with various plasma cell dyscrasias, including solitary plasmacytoma, smoldering myeloma, multiple myeloma, systemic light chain amyloidosis, and Waldenström's macroglobulinemia. The recommendations specific to the diagnosis and treatment of patients with newly diagnosed MM are discussed in this article.
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
Among patients with EGFR-mutant advanced NSCLC, EGFR TKIs are standard first-line therapy.
“Among patients with advanced non–small-cell lung cancer with a mutant epidermal growth factor receptor (EGFR), EGFR tyrosine kinase inhibitors (TKIs) are the standard first-line therapy.1–4”
From Osimertinib or Platinum–Pemetrexed in <i>EGFR</i> T790M–Positive Lung Cancer (2017) · cites this paper as [4]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Cites
Lenalidomide Maintenance after Stem-Cell Transplantation for Multiple Myeloma
Attal, M., Lauwers-Cances, V., Marit, G., Caillot, D., Moreau, P., Facon, T., Stoppa, A. M., Hulin, C., Benboubker, L., Garderet, L., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1114138 · Cited by 1,155 · see citing works
Lenalidomide after Stem-Cell Transplantation for Multiple Myeloma
McCarthy, P. L., Owzar, K., Hofmeister, C. C., Hurd, D. D., Hassoun, H., Richardson, P. G., Giralt, S., Stadtmauer, E. A., Weisdorf, D. J., Vij, R., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1114083 · Cited by 1,147 · see citing works
Self-citationDispenzieri, A., Kyle, R., Merlini, G., Miguel, J. S., Ludwig, H., Hajek, R., Palumbo, A., Jagannath, S., Blade, J., Lonial, S., et al. (2009) · Leukemia · doi:10.1038/leu.2008.307 · Cited by 815 · see citing works
Lenalidomide and Dexamethasone in Transplant-Ineligible Patients with Myeloma
Benboubker, L., Dimopoulos, M. A., Dispenzieri, A., Catalano, J., Belch, A. R., Cavo, M., Pinto, A., Weisel, K., Ludwig, H., Bahlis, N., et al. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1402551 · Cited by 793 · see citing works
Bisphosphonates in multiple myeloma: a network meta-analysis
Mhaskar, R., Redzepovic, J., Wheatley, K., Clark, O. A. C., Miladinovic, B., Glasmacher, A., Kumar, A., & Djulbegovic, B. (2012) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd003188.pub3 · Cited by 130 · see citing works
Management of multiple myeloma: a systematic review and critical appraisal of published studies
Kumar, A., Loughran, T., Alsina, M., Durie, B. G., & Djulbegovic, B. (2003) · The Lancet Oncology · doi:10.1016/s1470-2045(03)01077-5 · Cited by 113 · see citing works
Self-citation
Flagged first, then by citations
Cited by
Sorted by citations
Osimertinib or Platinum–Pemetrexed in <i>EGFR</i> T790M–Positive Lung Cancer
Mok, T. S., Wu, Y.-L., Ahn, M.-J., Garassino, M. C., Kim, H. R., Ramalingam, S. S., Shepherd, F. A., He, Y., Akamatsu, H., Theelen, W. S. M. E., et al. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1612674 · Cited by 3,379 · see citing works
Chim, C. S., Kumar, S. K., Orlowski, R. Z., Cook, G., Richardson, P. G., Gertz, M. A., Giralt, S., Mateos, M. V., Leleu, X., & Anderson, K. C. (2018) · Leukemia · doi:10.1038/leu.2017.329 · Cited by 305 · see citing works
Self-citationThe multiple myelomas — current concepts in cytogenetic classification and therapy
Kumar, S. K., & Rajkumar, S. V. (2018) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-018-0018-y · Cited by 302 · see citing works
Self-citationFonseca, R., Usmani, S. Z., Mehra, M., Slavcev, M., He, J., Cote, S., Lam, A., Ukropec, J., Maiese, E. M., Nair, S., et al. (2020) · BMC Cancer · doi:10.1186/s12885-020-07503-y · Cited by 127 · see citing works
Treatment options for triple-class refractory multiple myeloma.
Mikhael, J. (2020) · Clinical Lymphoma Myeloma and Leukemia · doi:10.1016/j.clml.2019.09.621 · Cited by 126 · see citing works
Raje, N., Roodman, G. D., Willenbacher, W., Shimizu, K., García-Sanz, R., Terpos, E., Kennedy, L., Sabatelli, L., Intorcia, M., & Hechmati, G. (2018) · Journal of Medical Economics · doi:10.1080/13696998.2018.1445634 · Cited by 25 · see citing works
Self-citation
- Authors
- Kumar, S. K., Callander, N. S., Alsina, M., Atanackovic, D., Biermann, J. S., Chandler, J. C., Costello, C., Faiman, M., Fung, H. C., Gasparetto, C., Godby, K., Hofmeister, C., Holmberg, L., Holstein, S., Huff, C. A., Kassim, A., Liedtke, M., Martin, T., Omel, J., Raje, N., Reu, F. J., Singhal, S., Somlo, G., Stockerl-Goldstein, K., Treon, S. P., Weber, D., Yahalom, J., Shead, D. A., & Kumar, R.
- Affiliations
- Seattle Cancer Care Alliance (US)
- University of Alabama at Birmingham (US)
- University of Wisconsin–Madison (US)
- Stanford Cancer Institute (US)
- Vanderbilt University (US)
- ORCID
- Kumar, Shaji K.
- Callander, Natalie S.
- Alsina, Melissa
- Atanackovic, Djordje
- Costello, Caitlin
- Faiman, Matthew
- Gasparetto, Cristina
- Hofmeister, Craig
- Holmberg, Leona
- Holstein, Sarah
- Huff, Carol Ann
- Kassim, Adetola
- Liedtke, Michaela
- Raje, Noopur
- Reu, Frederic J.
- Singhal, Seema
- Stockerl-Goldstein, Keith
- Treon, Steven P.
- Yahalom, Joachim
- Shead, Dorothy A.
- Venue
- Journal of the National Comprehensive Cancer Network
- Publisher
- Harborside Press, LLC
- Published
- 2017-02
- Volume
- 15
- Issue
- 2
- Pages
- 230-269
- ISSN
- 1540-1405 (ISSN-L)
- 1540-1413
- OpenAlex
- W2596138695
- Cited by
- 279
- References
- 6
- Citations by year
- 2026: 9 · 2025: 6 · 2024: 10 · 2023: 11 · 2022: 14 · 2021: 21 · 2020: 45 · 2019: 65 · 2018: 52 · 2017: 34 · 2016: 8 · 2015: 3
- FWCI
- 41.29
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- Journal of the National Comprehensive Cancer Network (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Hematology › Multiple Myeloma Research and Treatments
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Amyloidosis: Diagnosis, Treatment, Outcomes
- Health Sciences › Medicine › Oncology › Bone health and treatments
- Keywords
- multiple myeloma, plasma cell dyscrasia, newly diagnosed multiple myeloma, M protein, hypercalcemia, renal failure, anemia, infection, solitary plasmacytoma, smoldering multiple myeloma, systemic light chain amyloidosis, Waldenström macroglobulinemia, diagnosis, treatment
- MeSH terms
- Positron Emission Tomography Computed Tomography, Antineoplastic Agents, Antineoplastic Combined Chemotherapy Protocols, Humans, Immunoglobulins, Magnetic Resonance Imaging, Medical Oncology, Multiple Myeloma, Myeloma Proteins, Serologic Tests, Treatment Outcome, Chemotherapy, Adjuvant, Radiotherapy, Adjuvant, Stem Cell Transplantation, Asymptomatic Diseases, Standard of Care, Maintenance Chemotherapy
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
